Two ongoing Phase 2 clinical trials of CPX-351 to be showcased

Download PDF Copy

Editorial Checklist

Reviewed

Sep 4 2009

NewsGuard 100/100 Score

Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the Thomas Weisel Partners 2009 Healthcare Conference in Boston.

Mr. Jackson will provide a corporate overview and an update on the company's progress with two ongoing Phase 2 clinical trials of CPX-351 in newly diagnosed acute myeloid leukemia (AML) patients and first-relapse AML patients. The presentation will be given on Thursday, September 10, 2009 at 1:30pm EDT in the Blaxton Room of the Four Seasons Hotel.

Source:

http://www.celatorpharma.com

Posted in: Drug Trial News

Tags: Acute monocytic leukemia, Acute Myeloid Leukemia, Cancer, Cisplatin, Colorectal Cancer, Drug Delivery, Healthcare, Irinotecan, Leukemia, Myeloid Leukemia, Pharmaceuticals

Comments (0)

Download PDF Copy

Suggested Reading

Accelerating tobacco decline could boost global life expectancy

Accelerating tobacco decline could boost global life expectancy

New biomarkers offer hope for early detection and prevention of Alzheimer's

New biomarkers offer hope for early detection and prevention of Alzheimer's

Antibiotic resistance threatens millions of lives worldwide

Antibiotic resistance threatens millions of lives worldwide

Healthy lifestyle choices can offset genetic risk for brain diseases

Healthy lifestyle choices can offset genetic risk for brain diseases

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes

GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes

Study shows how a single defective BRCA1 gene accelerates cancer development

Study shows how a single defective BRCA1 gene accelerates cancer development

Combination therapy shows promising results in treating stage 3 melanoma

Combination therapy shows promising results in treating stage 3 melanoma

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care